Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature

Basit Öğe Kaydı
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorEryilmaz, Melek Karakurt
dc.date.accessioned2024-02-23T14:21:05Z
dc.date.available2024-02-23T14:21:05Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractWe wanted to present a case with coexistence of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangements that has been in remission for a long time with crizotinib. A 62-year-old nonsmoker male patient was diagnosed with Non-small cell lung cancer. Progression developed 9 months after the treatment, and coexistence of ALK and ROS1 positivity were detected in driver mutation analysis performed with fluorescent in situ hybridization. Crizotinib 2 x 250 mg was started in November 2016. The treatment of the patient, who has been in remission for approximately 55 months since then, continues. Until recently, the use of next-generation sequencing (NGS) was not common, but the more frequent epidermal growth factor receptor, then ALK, and finally ROS1 mutation were studied in tumor tissues. Sometimes ROS1 was not studied because there was not enough tissue left. We think that this rate will increase a little more with the widespread use of NGS from now on. Showing that ALK and ROS1 are positive together, longer survivals can be obtained by choosing therapies that are responsive to both.en_US
dc.identifier.doi10.1097/CAD.0000000000001224
dc.identifier.endpageE801en_US
dc.identifier.issn0959-4973
dc.identifier.issn1473-5741
dc.identifier.issue1en_US
dc.identifier.pmid34459458en_US
dc.identifier.scopus2-s2.0-85122714468en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpageE799en_US
dc.identifier.urihttps://doi.org/10.1097/CAD.0000000000001224
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13442
dc.identifier.volume33en_US
dc.identifier.wosWOS:000780317000109en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofAnti-Cancer Drugsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject1c-Ros Oncogene 1en_US
dc.subjectAnaplastic Lymphoma Kinaseen_US
dc.subjectCrizotiniben_US
dc.subjectCoexistenceen_US
dc.subjectRearrangementsen_US
dc.titleFifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literatureen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu